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Combined computational and intracellular
peptide library screening: towards a potent and
selective Fra1 inhibitor†
Miao Yu,a Lila Ghamsari,b Jim A. Rotolo,b Barry J. Kappelb and Jody M. Mason *a
To date, most research into the inhibition of oncogenic transcriptional regulator, Activator Protein 1
(AP-1), has focused on heterodimers of cJun and cFos. However, the Fra1 homologue remains an
important cancer target. Here we describe library design coupled with computational and intracellular
screening as an effective methodology to derive an antagonist that is selective for Fra1 relative to Jun
counterparts. To do so the isCAN computational tool was used to rapidly screen 475 million peptide
library members, narrowing the library size by 499.8% to one accessible to intracellular PCA selection.
The resulting 131 072-member library was predicted to contain high quality binders with both a high
likelihood of target engagement, while simultaneously avoiding homodimerization and off-target
interaction with Jun homologues. PCA screening was next performed to enrich those members that
meet these criteria. In particular, optimization was achieved via inclusion of options designed to
generate the potential for compromised intermolecular contacts in both desired and non-desired
species. This is an often-overlooked prerequisite in the conflicting design requirement of libraries that
must be selective for their target in the context of a range of alternative potential interactions. Here we
demonstrate that specificity is achieved via a combination of both hydrophobic and electrostatic
contacts as exhibited by the selected peptide (Fra1W). In vitro analysis of the desired Fra1–Fra1W inter-
action further validates high Fra1 affinity (917 nM) yet selective binding relative to Fra1W homodimers or
affinity for cJun. The isCAN - PCA based multidisciplinary approach provides a robust screening pipe-
line in generating target-specific hits, as well as new insight into rational peptide design in the search for
novel bZIP family inhibitors.
Introduction
Fra1 is an oncogenic transcription factor member of the basic
leucine zipper (bZIP) Fos family. Fos proteins (cFos, FosB, Fra1,
and Fra2) and Jun proteins (cJun, JunB, and JunD) heterodi-
merize via a leucine-zipper motif. An adjacent basic domain
binds to TPA-responsive element (TRE) DNA to form the
Activator Protein-1 (AP-1) complex. Fra1 is encoded by the
FOSL1 gene which is found to be highly expressed in multiple
tissue-specific cancers where it is associated with tumorigenesis
and cancer progression.1 Moreover, Fra1 is involved in neoplastic
transformation,2 motility,3 and cancer drug addiction.4 Hence,
the ability to selectively inhibit Fra1 represents a powerful
approach towards the treatment of many types of cancers, by
directly modulating oncogenic signals at the transcriptional
level. However, like many protein–protein interactions (PPIs),
targeting Fra1 is recognised as a significant challenge owing
to its traditional perception as an ‘‘undruggable’’ protein.5,6
It is considered intrinsically disordered and to become tran-
scriptionally active must both fold and heterodimerise via
many points of contact over broad and shallow surfaces. Fra1
therefore lacks the key hotspots that are required for inhibi-
tion by small molecules, making it difficult to functionally
inhibit its activity. Secondly, Fra1 is predominantly located in
the nucleus, meaning that targeting with antibody-based
approaches is technically impractical. To overcome these obsta-
cles, an alternative approach is to directly abrogate Fra1 onco-
genic function using an antagonistic peptide. We performed in-
cell library screening to derive peptide inhibitors capable of
functioning within the intracellular milieu that can selectively
bind with high affinity to Fra1 and disrupt its interactions with
other protein partners. The development of antagonists that
can function in this environment to sequester Fra1 is therefore
of great interest in therapeutic design and discovery.
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In particular, the coiled coil dimerization domain has been
the focus of much research since it is key in driving the highly
specific PPIs required for Fra1 activity. Specific details on coiled
coil formation have been discussed extensively elsewhere.7–16
Here we present the derivation of a peptide antagonist that is
selective for Fra1 in the presence of Jun-family members, and
that is also able to resist homodimerization. The sequence is
derived from a combination of in silico and intracellular library
screening to target the leucine zipper region of Fra1. In parti-
cular a computational semi-rational library design approach
was taken that explicitly considers all potential dimeric inter-
actions within the system, including user defined competitors
(all Jun family members). This provided a very large in silico
library from which peptides were ranked to produce a reduced
size, yet high quality library for in-cell screening using
protein fragment complementation assay (PCA). This approach
enabled the selection of library members with highest affinity
and selectivity for Fra1.
Results and discussion
Library design and isCAN strategy
Here we report the use of computational screening as a
mechanism to filter a large (75 582 720 member) library into a
smaller, yet higher quality library (131 072 member) to identify
peptides that can selectively target Fra1. In particular, by vastly
reducing the library size to remove members unlikely to fulfil
the desired criteria, it becomes readily accessible to our intra-
cellular screening approach, containing many members with
the predicted desired properties and therefore an increased
likelihood of highly selective binders. The approach makes
extensive use of the bZIP Coiled Coil Prediction Algorithm
(bCIPA),17,18 which works by predicting the Tm of a dimeric
coiled coil based only on primary sequence information. bCIPA
has been used as the basis for in silico tools that can mimic
both the Protein-fragment Complementary Assay (PCA) in
identifying high affinity coiled coils, and Competitive And
Negative Design Initiative (CANDI) to render them specific in
the presence of competitor sequences.18 The in silico PCA
(isPCA) and in silico CANDI (isCAN) equivalents (Fig. 1)20–22
can serve as useful tools in reducing much larger libraries, than
are accessible experimentally, to those that are smaller and of
high-quality. isCAN predicts the highest affinity peptides with
the largest difference between specified target and off-target
complexes (DTm).
19 This includes the potential for both target
and library homodimers, as well as multiple user-defined off-
targets. In utilizing the underlying bCIPA algorithm, isCAN
incorporates helical propensity, core, and electrostatic interac-
tions to provide a quantitative estimate of the interaction
affinities in the form of a Tm; the various functions within
the algorithm assign scores to the peptide–peptide interactions.
In addition to built-in frame alignment and prediction func-
tions, isCAN has a number of unique built-in check points.
These make use of the individual predictions relating to the
library (L), target (T), and competitor (C) peptides. Owing to
optimization of core and electrostatic residues found in
designed libraries, many peptide members are predicted to
be more stable as homodimeric complexes than as heterodi-
mers with the target. isCAN is therefore split into two sections:
the first set of calculations mirroring the PCA (isPCA section)
and the second introducing the competitor peptides (isCAN).
This stepwise calculation ensures that the processing time is
not wasted on library members that are predicted to preferen-
tially homodimerize or are unable to overcome the target
homodimer (and are therefore not ‘‘PCA-successful’’). A key
concept in both is the predicted DTm. It is the key determinant
behind the separation of successful and unsuccessful peptides
in the library.20–22
The 75 582 720 member peptide library designed to target
Fra1 corresponded to five heptad repeats of a leucine zipper
template (gabcdef). The initial isCAN step utilized three
Jun family members (cJun, JunB and JunD) as competitors.
Peptides to emerge from screening were required to possess
a predicted DTm Z 25 1C. This DTm cut-off was chosen
since it gave high confidence that the required selectivity
for Fra1 over Jun family members could be achieved, while
Fig. 1 Overview of the isPCA and isCAN protocols. Shown are desired and
numerous undesired states that can form upon combination of the library/
target/competitor peptides. Complexes screened within isPCA include
library–library, (negative), target–target (competitive) and library–target
(desired). Under isCAN, multiple user defined competitor sequences bring
about additional library–competitor (negative) and target–competitor
(competitive) complexes. Within isCAN, specificity is driven by the desired
predicted DTm value as specified by the user. Therefore, a library
member is only successful if it forms the desired complex with a predicted
Tm value greater than the DTm set by the user. Further details are discussed
elsewhere.20–22
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generating a library size that could be realistically represented
in PCA. Peptides meeting these criteria were predicted to be
capable of outcompeting all other possible complexes; i.e. to
overcome potential target–target, library–library, library–com-
petitor and target–competitor complexes (see experimental).
To facilitate this, the interfacial g, e, and a positions were
semi-randomized and screened in order to create a more
refined and reduced-size library for entry into PCA screening,
narrowing options presented at each semi-randomized position
to the more specific residues predicted to be required for Fra1
binding (Fig. 2).
A design principle of the library was to begin with an N-
terminal g position and end with a C-terminal e position to
maximise the potential for attractive/repulsive electrostatics,
with 15 semi-randomized positions of 3–5 options at each
position placed into the library sequence at positions corres-
ponding to core a hydrophobic and e/g electrostatic positions
within the heptad repeats (Fig. 2). The isCAN peptide library
was next narrowed to 485 sequences that met the requirements
of the DTm cut-off, which when degenerated created a PCA
accessible 131 072-member library (Fig. S1 and S2, ESI†). This
reduced the original library size by 499.8%, providing one with
Fig. 2 Fra1 library design and screening overview. During library design for isCAN screening peptide options were semi-randomized at all 10 e/g
positions (Q/E/K) and a positions (L/I/V/A and L/I/V/A/N at a3). The library illustrates the hydrophobic options at the core positions (a/d) and the charged/
polar options present at the flanking positions (e/g). In particular, positions g and e were semi-randomized with a view to generating potential attractive
and repulsive options with the corresponding positions of the target. Similarly, core a positions were semi-randomized to generate aliphatic hydrophobic
options. Positions c and d were fixed as A and L respectively (position b2 as Y for quantification purposes). The final PCA design arising from the isCAN
step (using cJun, JunB, and JunD competitors) resulted in a library size of 131 072 members (i.e. 499.8% library size reduction), with 13 randomised
positions of 2 or 4 options at each. The PCA library was derived by inspection of sequence variations within all 465 peptides predicted to display the
specified DTm of Z25 1C according to the isCAN software. Note that additional a position Thr residues in the PCA library were present owing to
unavoidable degenerate codon options. The helical wheel diagrams were generated using DrawCoil 1.0, http://www.grigoryanlab.org/drawcoil.23
Fig. 3 Protein-fragment complementation assay. Peptide library selection was undertaken in bacteria. During PCA, members that bind to the Fra1
leucine zipper recombine murine dihydrofolate reductase (mDHFR) and generate colonies under selective conditions (bacterial dihydrofolate reductase
is specifically inhibited using trimethoprim). Those peptides that bind with the highest affinity to the Fra1 target confer fastest cell growth rates. During
competition selection therefore, subsequent passages in liquid medium enrich potential PCA winners with the highest efficacy. Since PCA is performed in
the cytoplasm of E. coli, nonspecific, toxic, unstable, aggregation-prone (insoluble), and protease-susceptible members are removed.
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13 semi-randomised positions with 2 or 4 options at each
(Fig. 2). isCAN selected exclusively K at positions g2 and e2,
deeming it to be favourable for target binding while disfavour-
ing binding to all other species. Position a3 was limited to I/N,
g1 and e3 to Q/K, g3 and g4 to Q/E, e1, e4 and e5 to K/E, and a1,
a2, a4 and a5 to V/I/A/T (in constructing the PCA library, Thr
was unavoidably generated by degenerate codons). Accuracy
and variety of the constructed library was verified by DNA
sequencing as presented in ESI† (Fig. S1).
PCA selection winner
During PCA, one half of murine dihydrofolate reductase
(mDHFR) was genetically fused to the Fra1 target, and the
second half of mDHFR was fused to the protein library. Only
library members binding to the Fra1 target bring the two halves
of mDHFR together, rendering the enzyme active, and resulting
in bacterial colony formation under selective conditions
(Fig. 3). PCA also ensures that library members must overcome
target homodimers, and their own homodimerization to be
selected. Subsequent growth competitions under selective con-
ditions in liquid media enriched a ‘‘winning’’ peptide,
termed Fra1W.
Single step PCA selection was undertaken on M9 selective
agar media, followed by DNA sequencing and further rounds of
competition selection in liquid M9 medium, resulting in one
clean DNA sequence in the pool after ten rounds of competition
selection passaging (Fig. 3, 4 and Fig. S3, ESI†). The isCAN -
PCA selected sequence was named as Fra1W. Helical wheel
inspections of Fra1–Fra1W heterodimers and Fra1W homodi-
mers and cJun–Fra1W heterodimers (Fig. 4) illustrate the
hydrophobic interface at the core positions (a/d) and the
charged residues present at the flanking positions (e/g). Leu
residues found at core d positions were preserved to maintain
the leucine zipper. Fra1 and Fra1W heterodimer contains five
favourable electrostatic interactions between E and K at e and g
positions (blue hash). In contrast, the Fra1W homodimer
contained six unfavourable electrostatic interactions via K–K
alignment, with Fra1–cJun forming four unfavourable electro-
static interactions (K–K and K–R) and only one favourable
electrostatic (E–K) interaction. These interactions provide a
greater scope for stabilization of the target–antagonist complex
over other possibilities. At the core, Fra1 residues are atypical
and less favourable for hydrophobic interactions, with the a
position consisting of two T and two K residues. Fra1W displays
two A residues, two I residues and one V in establishing a
heterodimer with Fra1.
Circular dichroism
To demonstrate that the PCA-selected winner engages in inter-
action with Fra1 in a target-specific fashion, we synthesized
Fra1, cJun and Fra1W, analysed by electrospray MS (data shown
in supplementary documents) and characterized Fra1 homo-
dimers, Fra1W homodimers, cJun homodimers, and both
cJun–Fra1W and Fra1–Fra1W heterodimers. An analysis of the
global secondary structure content of homodimeric and hetero-
dimeric systems was conducted at a total peptide concentration
of 150 mM to provide equimolar concentrations of each com-
ponent helix for all dimeric systems. The 222/208 ratio was used
to provide evidence on whether the helices were monomeric or
adopted a quaternary structure.
Circular dichroism (CD) spectra confirmed that all samples
were broadly a-helical, with cJun and Fra1 samples only weakly
populated. In particular, CD spectra showed Fra1 to exist as
21% helical (Fig. 5a) with the 208 nm signal significantly
exceeding that of 222 nm, indicating low homodimeric affinity.
The secondary structure content of Fra1W in isolation dis-
played a 60% helical signature (Fig. 5b), with that of the
Fra1–Fra1W complex (Fig. 5c) exhibiting a more intense signal
with greater a-helical content (75%), more than three times that
of the target Fra1 in isolation. In addition, the 222/208 nm ratio
was 1.06, providing further evidence for a significant increase
in the helical stability of Fra1–Fra1W and evidence toward the
formation of a quaternary structure.24 Moreover, it clearly
demonstrated an increase from the averaged homomeric sig-
nals of Fra1 and Fra1W (Fig. 5d, red dash vs. black) at 20 1C
before thermal denaturation.
In contrast, the cJun–Fra1W signal superimposed with the
averaged homomeric signals (Fig. 6d, red dash vs. black line).
Fig. 4 Helical wheel representations of potential interactions with Fra1W. Fra1–Fra1W heterodimeric and Fra1W homodimeric helical wheel diagrams
illustrate the hydrophobic interface at the core positions (a/d) and the charged residues present at the flanking positions (e/g). Leu residues found at core
d positions were preserved to maintain the leucine zipper. The Fra1–Fra1W interaction contains favourable electrostatic (blue hash) and core interactions
to drive coiled coil formation. Fra1W–Fra1W and cJun–Fra1W display unfavourable electrostatic (red hash) interactions disfavouring their formation.
Helical wheel diagrams were generated using DrawCoil 1.0, http://www.grigoryanlab.org/drawcoil.23
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Overall this demonstrates that incubation of Fra1 with Fra1W
elicits a significant conformational change in the sample and
provides compelling evidence for the formation of a coiled coil.
Moreover, Fra1W selectively binds to Fra1 without interaction
with cJun.
Thermal denaturation profiles
Having observed a significant increase in the global secondary
structure content of the Fra1–Fra1W sample, we next sought to
quantify the stability of the complex by performing thermal
denaturation experiments (Fig. 7). In agreement with the
spectra, this pattern of increased stability between undesired
and desired complexes was also observed using thermal melts
taken in 1 1C increments. Neither Fra1 or cJun in isolation
formed a coiled coil complex; rather, only the upper baseline
characteristic of the profiles was observed (Fig. 7a and b, blue).
This is in agreement with spectral data and is indicative of a
weakly populated helix that does not self-associate. However,
when Fra1 was incubated with the Fra1W antagonist peptide,
the intensity of the helical signal increased significantly and led
to a transition midpoint of 64 1C (Fig. 7b, black line) while no
interaction occurred between cJun and Fra1W; rather a super-
imposition of the cJun–Fra1W (Fig. 7a, black line; Tm = 40 1C)
with the averaged homomeric cJun and Fra1W (Fig. 7a, red
dash line) was observed. The instability of Fra1W (Fig. 7a and b,
green line; Tm = 48 1C) in isolation, relative to Fra1–Fra1W is a
considerable advantage (Tm = 48 1C vs. 64 1C), removing the
possibility of homodimer formation as a potential off-target. As
can be observed the peptide preferentially heterodimerises
with Fra1.
To provide further evidence for the preferential binding of
Fra1W to Fra1 over cJun, and that Fra1W was able to interrupt a
Fra1–cJun interaction, dimer exchange experiments were per-
formed at equimolar concentrations of each peptide. First cJun
was added to a heteromeric sample containing Fra1–Fra1W; in
this case the component spectra of Fra1–Fra1W and cJun
superimposed with that of the three combined, indicating that
no exchange of binding partner had occurred (Fig. 8a; black
observed vs. red hash average). However, when Fra1 was added
to a heteromeric sample containing cJun–Fra1W, the CD signal
Fig. 5 CD spectra data indicates a Fra1–Fra1W interaction. Shown are CD spectra for (a) Fra1 (b) Fra1W and (c) the samples mixed at 1 : 1 stoichiometry.
Spectra were measured at 20 1C, 5 1C, and again post thermal denaturation at 20 1C (PM20oC: to establish that unfolding is fully reversible) at a total
peptide concentration of 150 mM and presented as mean residue ellipticity (MRE). (d) CD spectra are shown at 20 1C for Fra1 and Fra1W in isolation and
when mixed, demonstrating a significant gain in measured signal (black) over the average of the two component signals (red hash). All spectra are
indicative of helical structures. All experiments were performed in 10 mM potassium phosphate and 100 mM potassium fluoride (pH 7.0).
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Fig. 6 CD spectra data indicates no cJun–Fra1W interaction. Shown are CD spectra for (a) cJun, (b) Fra1W and (c) cJun–Fra1W. (d) CD spectra are
shown at 20 1C for cJun and Fra1W in isolation and when mixed, demonstrating no gain in measured signal (black) over the average of the two
component signals (red hash). Spectra were measured at 20 1C, 5 1C, and again post thermal denaturation at 20 1C (PM20oC: to establish that unfolding is
fully reversible) at a total peptide concentration of 150 mM and presented as mean residue ellipticity (MRE). All spectra are indicative of helical structures.
All experiments were performed in 10 mM potassium phosphate and 100 mM potassium fluoride (pH 7.0).
Fig. 7 CD thermal denaturation profiles demonstrate that Fra1W interacts with Fra1 but not cJun. Shown are thermal stability of peptide pairs measured
via temperature dependence of the CD signal at 222 nm. (a) The thermal denaturation profile cJun–Fra1W indicates no difference from the average of the
component peptides (black line vs. red hash) indicating no interaction. (b) Fra1–Fra1W shows a substantial increase in the transition midpoint (Tm = 64 1C)
relative to component peptides (black vs. red hash). All experiments were performed in 10 mM potassium phosphate and 100 mM potassium fluoride
(pH 7.0). All spectra were recorded at 1 1C increments at a total peptide concentration of 150 mM and fitted to a two-state denaturation model.
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increased from the average of the component samples (Fig. 8b;
black observed vs. red hash average). Similarly, when Fra1W
was added to a solution containing Fra1–cJun an increase in
signal was observed, providing further evidence for the ability
of Fra1W to compete off cJun from Fra1 (Fig. 8c). Reassuringly,
the signals for the three combined peptides from all three
experiments were found to superimpose (Fig. 8d), demonstrat-
ing that both samples had equilibrated to generate the same
helical signature. These experiments provide firm evidence that
Fra1W preferentially binds Fra1, interrupts a Fra1–cJun inter-
action, and that cJun is unable to interrupt the heterodimeric
Fra1–Fra1W complex.
Size-exclusion chromatography (SEC)
To further confirm that Fra1W preferentially and specifically
binds to Fra1 in a dimeric state, size-exclusion chromatography
(SEC) was performed. Monomeric profiles for cJun (Fig. 9a, blue
line), Fra1 (Fig. 9b, blue line), Fra1W (Fig. 9a and b, green line)
and cJun–Fra1W (Fig. 9a, black line) all eluted at approximately
20 min. These were in contrast to the dimeric profile of Fra1–
Fra1W (Fig. 9b, black line), which eluted one minute earlier at
approximately 19 min. In all cases, the elution profiles were
consistent with predicted monomer/dimer patterns according
to characterised cFos (monomer – 20 min) and cJun–FosW
(dimer – 18.5 min) standards,25 demonstrating that the only
observed dimer was the Fra1–Fra1W complex.
Isothermal titration calorimetry (ITC)
To provide further insight to the origin of the binding affinity
(KD) between Fra1 and Fra1W, the relative contributions of
enthalpy versus entropy to the affinities were dissected. Iso-
thermal Titration Calorimetry (ITC) experiments were con-
ducted to enable the free energy of binding to be split into
entropic and enthalpic components (Fig. 10), while also provid-
ing a stoichiometric measure of binding (N = 1.06). The
thermodynamic parameters determined from ITC measure-
ments on Fra1–Fra1W further confirmed the interaction; titrat-
ing a solution of Fra1W into Fra1 elicited the expected
sigmoidal binding curve of a high affinity interaction, with
the fit deriving a KD of 917 nM (DG = 8.0 kcal mol1). The free
energy of binding was found to be predominantly driven by a
favourable enthalpic component (DH = 5.6 kcal mol1) with
Fig. 8 CD dimer exchange experiments demonstrate that Fra1W binds Fra1 but not cJun. (a) Addition of cJun to a solution containing Fra1–Fra1W led to
no change in signal. (b) Adding Fra1 to a solution containing cJun–Fra1W led to an increase in helical signature, consistent with dimer exchange. (d)
Addition of Fra1W to a solution containing Fra1–cJun led to an increase in helical signature, consistent with dimer exchange. (d) equilibrated signals from
mixtures (a)–(c) superimpose as expected. Spectra were measured at 20 1C at a total peptide concentration of 150 mM containing equimolar
concentrations of each peptide and presented as mean residue ellipticity (MRE). All experiments were performed in 10 mM potassium phosphate and
100 mM potassium fluoride (pH 7.0). All three plots share the same y-axis.
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an additional favourable overall entropic component (TDS =
2.4 kcal mol1).
Luciferase gene reporter
Having establishing target engagement for the Fra1W peptide,
its ability to inhibit Fra1 transcriptional activity was assessed
using an AP-1 luciferase gene reporter assay. An A549 lung
carcinoma cell line expressing a high level of Fra127 was
transfected either with a vector expressing a firefly luciferase
gene under the control of multimerized AP-1 responsive
elements located upstream of a minimal promoter, or with a
non-inducible firefly luciferase vector as negative control.
We synthesized a cell penetrant version of Fra1W peptide
(Fra1W–NLS–Tat) and treated the cells with increasing amounts
Fig. 9 SEC profiles indicate that Fra1W binds Fra1 but does not homodimerize or bind cJun. Shown are size exclusion chromatography profiles for (a)
noninteracting and (b) interacting peptides. A peak at approximately 19 min for the Fra1–Fra1W mixture (b – black trace) represents a dimeric sample
whilst cJun, Fra1, Fra1W and cJun–Fra1W generate a peak at approximately 20 min, indicating monomeric samples. These experiments, undertaken at a
total peptide concentration of 20 mM, provide additional evidence for selectivity of the Fra1–Fra1W interaction. Arrows show previously characterised
controls with elution times for a 32mer Fos monomeric peptide (20 min) and a 37mer cJun–FosW heterodimer (18.5 min).25
Fig. 10 Isothermal titration calorimetry analysis of the Fra1–Fra1W interaction. On the fitted data plot, the solid line represents the fit to the data based
on the binding of a ligand to a macromolecule using the MicroCal (GE Healthcare) Origin software.26 See Materials and methods for further details.
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of the fusion peptide. AP-1 activity was instigated by the
addition of 10 nM PMA six hours prior to the addition of the
firefly luciferase substrate. Fra1W induced a dose-dependent
reduction in luciferase activity (Fig. 11), demonstrating that
when fused to a cell penetration domain, Fra1W peptide was
able to enter the cell and impact upon AP-1 activity. Addition-
ally, no cytotoxicity was observed in A549 cells after 24 hours
treatment across the concentrations of the peptide tested
(0 to 20 mM) (Fig. S6, ESI†).
Conclusion
To date, the majority of research into Activator Protein 1 (AP-1)
inhibition has focused on cJun and cFos. However, other AP-1
subunits, such as Fra1, are established oncogenic proteins
that are implicated in a number of different cancers1–4 that
include colon28 squamous cell,29 and lung carcinomas.27 Here
we describe a semi-rational library design approach combined
with in silico and intracellular paired library screening to
demonstrate an effective strategy towards the identification of
target-specific bZIP antagonists. In particular, the isCAN library
screen20–22 paired with PCA has been used to identify peptides
that selectively engage with Fra1, while removing members
with a range of non-desired features such as the ability to
homodimerize, those unable to outcompete target homodi-
mers, and additionally considering potential library–competi-
tor and target–competitor interactions (i.e. competitors cJun,
JunB, JunD). Following the isCAN step, 499.8% of the library
was removed, allowing the remaining 131 072 sequences to be
accessible to the intracellular PCA, resulting in a highly selec-
tive nM affinity antagonist of Fra1. Of note within this process
is that Fra1W was ranked 13th out of 485 peptides (top 3%) to
emerge from the isCAN screen. Moreover, since residue varia-
tions within the 485 peptides degenerated to create a library of
131 072 for the PCA scan, the peptide identified is within the
top 0.01% of all predicted sequences to enter the PCA step,
giving considerable confidence in the system.
An important part of the screening approach is the inclusion
of options that generate both favourable and compromised
intermolecular contacts within the desired species. This over-
looked prerequisite acts to define PPIs which are stable, while
blocking the formation of otherwise energetically accessible
alternatives. Formation of the Fra1–Fra1W heterodimer results
from five favourable E–K electrostatic interactions between e
and g residues. The formation of a Fra1W homodimer is
destabilized via six unfavourable electrostatic K–K pairs. These
provide greater scope for stabilization of antagonist–target
heterodimeric complexes, destabilize antagonist homodimers,
and enhance overall interaction specificity.25,30–32 Residues
within the Fra1 core are atypical and less favourable for hydro-
phobic interaction; however, Fra1W displays a hydrophobic
core, consisting of I, V, as well as smaller A sidechains, to
establish favourable interactions with Fra1. Reassuringly, in
combination with the electrostatic component, the permuta-
tion of these aliphatic hydrophobics within Fra1W does not
disproportionately favour interaction as a homodimer or with
cJun. Rather, it is shown that specificity is achieved using a
combination of both hydrophobics and electrostatics. Hetero-
dimerisation of Fra1W with cJun/JunB/JunD is prevented via
four K/R repulsions. In vitro analysis via a combination of CD,
SEC and ITC validates the isCAN - PCA approach and demon-
strates that Fra1W is able to specifically interact with Fra1 while
avoiding homodimerization or interactions with off-target cJun.
Luciferase gene reporter experiments, in which Fra1W is fused
to an NLS–Tat cell penetrating peptide, additionally demon-
strates that the peptide can enter A549 lung cancer cells,
impacting upon AP-1 Fra1 transcriptional activity in a dose
dependent manner. Heterodimers of Fra1–Fra1W are estab-
lished to be dimeric in nature and cannot be disrupted by the
addition of cJun. Interaction with other Jun homologues is
unlikely since (i) JunB and JunD were explicitly considered
during the isCAN step and (ii) all Jun family members share
the same a/d core (a major driver in coiled coil stability)
with only two e/g residue differences between cJun and Jun B
(Fig. S5 – g3 Q-to-E and e3 A-to-S, ESI;† JunD is identical at the
interface). We are therefore confident that Fra1W does not
interact with any Jun homologue.
Although the ability to select between Fos members, was not
an aim of this study, we believe that it is unlikely to present an
issue. In particular; (i) individual AP-1 members are known
to be driven by unique temporal and tissue-specific
patterns, impacting upon different target genes.36 Therefore,
a key feature in targeting the correct Fos homologue is not only
the ability to impart selectivity, but the ability to deliver the
peptide to the particular cell in which the target protein
homologue is overexpressed. This has been achieved for exam-
ple by targeting cancer cells that overexpress specific popula-
tions of cell surface receptors that are highly expressed
in specific cancers, thereby serving as physiological targets
for therapeutic delivery. Indeed, receptor-mediated drug deliv-
ery presents an emerging opportunity to enhance therapeutic
Fig. 11 Fra1 antagonist peptide reduced AP-1 mediated transcriptional
activity in A549 cells. Cells were induced with 10 nM PMA and the
expression of the luciferase reporter gene from either AP-1 responsive
elements (AP-1 inducible vector) or random response elements (non-
inducible vector) were measured 24 h after treatment with Fra1W–NLS–
Tat. The peptide reduced the transactivation of luciferase gene expression
in a dose-dependent manner from the inducible AP-1 response element.
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efficiency by accumulating the drug within the tissue of interest
where the target resides, thereby reducing undesired, off-target
effects;33 (ii) since Fra1 must heterodimerise with a Jun family
member to become active, selectivity for Fra1 in the context of
the Jun protein family remains key in blocking Fra1 driven
transcriptional activity; (iii) as we have shown previously,17
native heterodimers between Jun/Fos family members are also
non-specific according to affinities between the various combi-
nations, again suggesting that unique temporal and tissue-
specific expression patterns are the major drivers in determin-
ing the precise AP-1 composition; (iv) lastly, the Fos family
exists with minimal differences between members, with cFos/
FosB/Fra1/Fra2 all sharing an identical a/d core. There are only
three minor e/g residue changes from Fra1 (Fig. S5 – e3 Q-to-E
for FosB, e4 Q-to-L for cFos, and g5 Q-to-E for cFos/FosB/Fra2,
ESI†). Overall, these changes are very modest, and therefore
Fra1W is not expected to be capable of discerning between Fos
family members.
Future structural biology approaches may be employed to
provide further insight into the mechanism of Fra1–Fra1W
interaction, while introduction of macrocyclic structures into
the Fra1W framework may provide the ability to further
strengthen binding activity. Addition of cell penetrating pep-
tide motifs and/or other moieties to facilitate receptor-
mediated drug delivery may be required to impart further
selectivity in delivering peptide derivatives to their intracellular
target. In conclusion, the isCAN - PCA library-based multi-
disciplinary approach harbours significant potential in the
search for potent and selective PPI inhibitors, with the potential
to deliver further insight into rational peptide-based drug
design towards use in the clinic.
Experimental
A 75 582 720 member peptide library was designed by introdu-
cing semi-randomised residue options at positions corres-
ponding to key interfacial positions within each heptad
repeat of a coiled-coil motif (gabcdef). The library was next
screened using isCAN software based on the bCIPA algorithm,
which has been described in detail elsewhere.20–22,25,34 Briefly,
the software provides a qualitative rank of affinity by estimating
the thermal melting point (Tm) of every potential dimeric
interaction within the system. In this library, every g and e
position within the coiled coil, which are critical in forming
electrostatic contacts within a coiled-coil sequence19 were semi-
randomized to generate Q/E/K options, with a view to generat-
ing both potential attractive and repulsive options with the
corresponding positions of the target (Fig. 2). Similarly, all a
positions corresponding to the core region within a coiled-coil
sequence (a1, a2, a4, a5) were semi-randomized to generate
L/I/V/A options. The a3 position was semi-randomized to
additionally generate an Asn option (L/I/V/A/N). All c and d
positions were fixed as A and L, respectively, to impart helicity
and further core hydrophobicity that is characteristic of the
parallel dimeric coiled-coil motif.20 Using the in silico CANDI
(isCAN) software, all peptide library members were next com-
putationally screened for predicted affinities in the form of a
Tm. During isCAN the stability of every member was considered
as (i) a homodimer, (ii) with the Fra1 target, and (iii) as a
potential heterodimer with off-target competitors cJun,
JunB and JunD, as well as (iv) the stability of any potential
target–target complex, or (v) target–competitor complexes. To
distinguish between desired (library–target) and non-desired
interactions (target–target, target–competitor, library–library,
library–competitor interactions), a lowest acceptable predicted
DTm was defined as 25 1C (Fig. 1). isCAN is split into two
sections: the first set of calculations mirroring the PCA (isPCA)
and the second introducing the competitor peptides (isCAN).
This stepwise calculation ensures that processing time is not
wasted on library members that are predicted to preferentially
homodimerize or are unable to overcome the target homodi-
mer (and are therefore not ‘‘PCA-successful’’). A key concept in
both is the predicted differences in Tm (DTm). It is the key
determinant behind the separation of successful and unsuc-
cessful peptides in the library. PCA-successful library members
then have their desired state Tm compared with library
member-competitor Tm values and the ‘‘CANDI-successful’’
library members are finally exported.20,22 The library subset
remaining was next screened in order to reduce residue options
4500 fold to create a small yet high quality library that was
accessible to intracellular PCA screening (Fig. 3).
PCA and expression vector cloning
PCA has been extensively used to derive PPI antagonists of AP-
1.17,35 Briefly, mDHFR was split and one half fused to the Fra1
leucine zipper target and the other half to the library. Only
target binding library members bring two halves of mDHFR
into the proximity with each other, render it active, and lead to
colony formation under M9 selective conditions. Trimethoprim
was used to selectively inhibit bacterial DHFR, thereby ensuring
that colonies can arise only as the result of an interaction
between Fra1 and a peptide library member. The Fra1 gene was
synthesized using overlap extension polymerase chain reaction
by two pair of primers: Fra1 forward: 50-ATA ATA GCT AGC CTG
ACC GAT TTT CTG CAG GCG GAA ACC GAT AAA CTG GAA GAT
GAA AAA AGC GGC CTG CAG CGC G-3 0; Fra1 reverse: 50-ATA
ATA CGG CGC GCC TTC CAG GCG TTC TTT CTG TTT CTG CAG
TTC TTC AAT CTC GCG CTG CAG GCC GC-30 and cloned into
the pES300d vector system using NheI and AscI restriction sites.
PCA library construction
Primers were designed such that the desired library could be
generated using overlap-extension PCR. Degenerate codons
were introduced into a non-overlapping region of the primers
to generate an approximate annealing temperature of 38 1C.
Correct amplification was enabled via an elongated reverse
primer and verified by agarose gel electrophoresis. The correct
PCR product was then digested using NheI and AscI restriction
enzymes for subcloning the library into the pES230d vector
(restriction enzyme recognition sites shown). Primer sequences
used were Fra1-Lib-forward: 50-ATA ATT GCT AGC MAR RYA
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GCG GCA CTG RAR CAG AAG RYC TAT GCG CTG AAG CAG SAR
AWC GCG GCC CTG-30 and Fra1-Lib-reverse: 50-AAA AAA AGG
CGC GCC YTY CAG TGC CGC TRY YTY CTG YTY CAG TGC CGC
GRY YTS TTT YTK CAG GGC CGC G-30.
Single-step selection PCA
Escherichia coli XL-1 cells were used for construction and
cloning of libraries as described previously.17 First, pES300d–
Fra1 target and pREP4 (for expression of the Lac repressor
protein; Qiagen) were co-transformed into BL21–gold cells
(Stratagene) and plated onto LB agar with the appropriate
antibiotics (kanamycin and chloramphenicol). These cells were
next made electrocompetent before transformation with the
pES230d–Fra1–PCA-library plasmid. Transformed cells were
plated onto three different media. 1/20th of the cells were
plated onto LB agar with three antibiotics (kanamycin,
ampicillin, and chloramphenicol) as a positive control of
transformation efficiency. Another 1/20th of the solution
was plated onto M9 minimal agar containing 1 mg mL1
trimethoprim and the same three antibiotics as a negative
control. Finally, the remaining 90% of the transformed cells
were plated onto M9 minimal agar in the presence of the three
antibiotics, 1 mg mL1 trimethoprim, and 1 mM isopropyl b-D-
thiogalactopyranoside (IPTG) to induce expression of the two
dihydrofolate reductase fragment-fused peptides. This single-
step selection led to B200 colonies from the initial library of
131 072, meaning that 99.8% of all PCA library members were
removed at this stage owing to their inability to effectively bind
Fra1 or to rescue cell growth.
Competition selection PCA
To increase selection stringency, growth competition experi-
ments were undertaken. Selected colonies were pooled from
the plate and grown in M9 minimal media under selective
conditions (containing kanamycin, ampicillin, chlorampheni-
col, trimethoprim, and IPTG), and serially diluted over pas-
sages. Using these sequential rounds of competition selection,
subtle differences in growth rate can become amplified,
increasing the stringency of selection relative to the single-
step method. Competition selection therefore allows the most
effective one or two sequences to be isolated from the whole
population of Fra1 binders initially identified during single-
step selection. At each passage, glycerol stocks were prepared,
and sequencing results were obtained (Eurofins Genomics
Germany GmbH, Germany) for DNA pools and individual
colonies. For each passage, 50 mL of liquid culture was added
to 50 mL of fresh M9 minimal media, resulting in an A600 of
B0.01. Cells were incubated at 37 1C until an A600 of B0.4 was
reached before moving to the next passage. Ten rounds of
competition selection were performed before the pool was
found to contain one clean sequence; Fra1W: KAAALKQKA-
YALKQQIAALKKQVAALKQKIAALK.
Peptide synthesis
Rink amide ChemMatrix resin was obtained from PCAS
Biomatrix, Inc. (Saint-Jean-sur-Richelieu, QC). Fmoc-L-amino
acids and benzotriazol-1-yl-oxytripyrrolidino-phosphonium
hexafluorophosphate (PyBOP) were obtained from Merck. All
other reagents were of peptide synthesis grade and obtained
from Thermo Fisher Scientific (Loughborough, U.K.). Peptides
were synthesized on a 0.1 mmol scale on a PCAS ChemMatrix
Rink amide resin using a Liberty Blue microwave peptide
synthesizer (CEM, Matthews, NC) employing Fmoc solid-phase
techniques20 with repeated steps of coupling, deprotection,
and washing (4  5 mL of dimethylformamide). Coupling
was performed using Fmoc amino acid (5 equiv.), PyBOP
(4.5 equiv.), and diisopropylethylamine (10 equiv.) in dimethyl-
formamide (5 mL) and subjected to 35 W microwave irradiation
at 90 1C for 30 min. Deprotection was performed as follows:
piperidine (20%) in dimethylformamide was subjected to 30 W
microwave irradiation at 80 1C for 5 min. Following synthesis,
peptides were acetylated using acetic anhydride (3 equiv.)
and diisopropylethylamine (4.5 equiv.) in dimethylformamide
(2.63 mL) for 20 min, followed by cleavage from the resin with
concomitant removal of side-chain-protecting groups by treat-
ment with a cleavage mixture (10 mL) consisting of TFA (95%),
triisopropylsilane (2.5%), and H2O (2.5%) for 4 h at room
temperature. The suspended resin was removed by filtration,
and the peptide was precipitated using four rounds of crashing
in ice-cold diethyl ether, vortexing, and centrifuging. The pellet
was then dissolved in a 1 : 1 MeCN/H2O mixture and freeze-
dried. Purification was achieved via reverse-phase high-
performance liquid chromatography (RP-HPLC) using a Phe-
nomenex Jupiter Proteo (C18) reverse-phase column (4 mm,
90 Å, 21.2 mm inner diameter  250 mm length). The following
eluents were used: 0.1% TFA in H2O (a) and 0.1% TFA in ACN
(b). The peptide was eluted by applying a linear gradient (at
15 mL min1) of 20 to 50% of 0.1% TFA in ACN (b) over 30 min.
The fractions that were collected were examined by electrospray
MS, and those found to contain exclusively the desired product
were pooled and lyophilized. Analysis of the purified final
product by RP-HPLC indicated a purity of 495% (Fig. S4, ESI†).
Circular dichroism
CD was carried out using an Applied Photophysics Chirascan
CD apparatus (Leatherhead, UK) using a 200 mL sample in a CD
cell with a 1 mm path length. Samples contained 150 mM total
peptide (Pt) concentration at equimolar concentration for
heterodimeric solutions (i.e., 75 mM per peptide) and sus-
pended in 10 mM potassium phosphate and 100 mM potas-
sium fluoride at pH 7.0 prior to analysis. The CD spectra of
samples were scanned between 300 nm and 190 nm in 1 nm
steps, averaging 0.5 s at each wavelength. Three scans were
averaged at 20 1C, 5 1C and once again at 20 1C after thermal
denaturation to assess helical levels and the ability of the
coiled-coil structure to refold.
Thermal denaturation experiments
Thermal denaturation experiments were performed at 150 mM
of total protein concentration in 10 mM potassium phosphate
and 100 mM potassium fluoride, pH 7, using an Applied
Photophysics Chirascan CD instrument (Leatherhead, UK).
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The temperature ramp was set to stepping mode using 1 1C
increments and paused for 30 s at each temperature before
measuring ellipticity at 222 nm. For all temperature denatura-
tion experiments, data collection was started at 0 1C, and at this
temperature, the peptide solutions remained aqueous. Data
collection continued to 90 1C. Data points for thermal dena-
turation profiles represent the averaged signal after 4 s of data
collection. Melting profiles were Z95% reversible with equili-
brium denaturation curves fitted to a two-state model, derived
via modification of the Gibbs–Helmholtz equation,34 to yield
the melting temperature (Tm). Melting profiles for heterodi-
mers are clearly distinct from averages of constituent homo-
dimeric melts, indicating that helices form heterodimeric
complexes, with the cooperative nature of the melting profiles
suggesting an apparent two-state process. Tm values were
determined by least-squares fitting of the denaturation assum-
ing a two-state folding model widely used for coiled coils34 and
provided an excellent fit to our data.
Isothermal titration calorimetry (ITC)
ITC measurements were made using a Microcal VP-ITC instru-
ment with data collected and processed using the Origin 7.0
software package. All measurements were carried out at least
two times. Briefly, all peptides were studied at 20 1C in 10 mM
potassium phosphate and 100 mM potassium fluoride at pH
7.0. 500 mL of Fra1W was loaded into the syringe at 100 mM
peptide concentration. 2000 mL of Fra1 was loaded into the cell
at 10 mM. The experiment was undertaken by injecting 10 mL 
30 injections of Fra1W into the calorimetric cell. The change in
thermal power as a function of each injection was automatically
recorded using the Microcal Origin software and the raw
data were integrated to yield ITC isotherms of heat release
per injection as a function of Fra1W to Fra1 Molar ratio.
No precipitation of protein was observed in any of the experi-
ments undertaken. Following ITC measurements, the data were
fit to a one-site model:26
q(i) = ((nDHVP)/2)[1 + (L/nP) + (Kd/nP)] 
[[1 + (L/nP) + (Kd + nP)]2  (4L/nP)]1/2
where q(i) is the heat release (kcal mol1) for the ith injection, n
is the stoichiometry of heterodimerisation, V is the effective
volume of protein sample loaded into the calorimetric cell
(1.46 mL), P is the total Fra1 concentration in the calorimetric
cell (mM) and L is the total Fra1W concentration in the calori-
metric cell at the end of each injection (mM). This model is
derived from the binding of a ligand to a macromolecule using
the law of mass action (assuming a 1 : 1 stoichiometry) to
extract the various thermodynamic parameters,26 namely the
apparent equilibrium constant (KD) and the enthalpy change
(DH) associated with heterodimerisation. The free energy
change (DGbind) upon ligand binding can be calculated from
the relationship:26
DGbind = RT ln KD
where R is the universal molar gas constant (1.9872 cal K1 mol1),
T is the absolute temperature in Kelvin (293.15 K) and KD is the
dissociation constant of binding with units of mol L1. Finally,
the entropic contribution (TDS) to the free energy of binding
was calculated using the derived values of DH and DGbind.
Size-exclusion chromatography
Size-exclusion experiments were performed at room tempera-
ture using a Superdex Peptide 10/300 GL column (GE Health-
care Life Sciences) by injecting 100 mL of a 20 mM (total peptide
concentration) sample in 10 mM potassium phosphate and
100 mM potassium fluoride, pH 7.0 and at a flow rate of
0.5 mL min1. Elution profiles were recorded via absorbance
measurements at A280.
Luciferase gene reporter experiments
The AP-1 reporter assay was performed in a A549 lung carci-
noma cell line using an AP-1 reporter kit (BPS Bioscience, San
Diego, CA, USA). Cells were seeded at a density of 20 000 cells
per wells of a white opaque 96-well plate, and transfected
with either the reporter vector or the negative control vector
using TransIT-LT1 transfection reagent (Mirus Bio, WI, USA).
Twenty-four hours post transfection, the culture medium was
exchanged with low FBS assay medium and the cells were
treated with given concentrations of Fra1W diluted in the assay
medium. The AP-1 transcriptional activity was stimulated with
10 nM PMA 18 hours after peptide treatment. Six hours after
PMA stimulation, the cells were lysed and the Firefly luciferase
activity was measured using the Firefly luciferase reagent (BPS
Bioscience, San Diego, CA, USA).
Measurement of cell viability
A549 cells were seeded at a density of 20 000 cells per wells of a
black opaque 96-well plate. The cells were treated exactly as
described in the Luciferase gene reporter experiment section.
Twenty-four hours post peptide treatment, the cell viabilities
were measured using CellTiter Blue (Promega Inc.) according to
the manufacturer’s instruction.
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